2 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsNeoplasm, Residual, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorderRecruitingPhase 32026-08-06NCT05232916
MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD PatientsAcute Graft Versus Host Disease in Intestine; Steroid Refractory GVHDActive, not recruitingPhase 32024-10-17NCT04769895